AstraZeneca vs Mastercard: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: AstraZeneca and Mastercard side by side

1. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

2. 1966Mastercard

   Interbank Card Association Takes Shape

   A group of U.S. Banks formed the Interbank Card Association to make card acceptance work across institutions rather than inside isolated bank programs.

3. 1968Mastercard

   Master Charge Brand Adopted

   The association adopted the Master Charge name and interlocking-circle design to give member banks a stronger shared identity. A common brand made the network easier for merchants and consumers to recognize as acceptance expanded beyond local bank programs.

4. 1979Mastercard

   Master Charge Becomes MasterCard

   The network changed its name from Master Charge to MasterCard as it became more international. The rebrand simplified recognition and helped the company present itself as a global acceptance network rather than a domestic bank-card association.

5. 1993AstraZeneca

   Zeneca Group Spun Off from ICI

   Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

6. 1999AstraZeneca

   Astra and Zeneca Merge to Form AstraZeneca

   The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

7. 2000AstraZeneca

   Nexium Launch Replaces Prilosec

   AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

8. 2002Mastercard

   Europay Merger and Corporate Conversion

   MasterCard merged with Europay International and converted from a membership association into a private share corporation. That structure prepared the company for public-market ownership and a more independent investment agenda.

9. 2006AstraZeneca

   Acquisition of Cambridge Antibody Technology

   AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

10. 2006Mastercard

    Initial Public Offering on the NYSE

    MasterCard priced its initial public offering at $39 per share and listed on the New York Stock Exchange under the symbol MA.

11. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

12. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

13. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

14. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

15. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

16. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

17. 2017Mastercard

    Vocalink Expands Real-Time Payments

    Mastercard completed its Vocalink acquisition after announcing a deal for 92.4 percent of the U.K. Payments infrastructure company for about $920 million.

18. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

19. 2020Mastercard

    Finicity Strengthens Open Banking

    Mastercard completed the acquisition of Finicity, a North American financial data and open banking platform. The deal added consumer-permissioned data connectivity for lending, account verification, personal finance, and account-based payment use cases.

20. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

21. 2021Mastercard

    Michael Miebach Becomes CEO

    Michael Miebach became chief executive officer on January 1, 2021 after serving as chief product officer and president.

22. 2021Mastercard

    Nets Account-to-Account Business Closes

    Mastercard completed the acquisition of the majority of Nets' Corporate Services business, adding clearing and settlement instant payment infrastructure, bill payment, and e-invoicing capabilities.

23. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

24. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

25. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

26. 2024Mastercard

    Recorded Future Adds Threat Intelligence

    Mastercard completed the acquisition of Recorded Future, adding AI-enabled threat intelligence to its cybersecurity, identity, and real-time fraud scoring services.

27. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

28. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

29. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

30. 2025Mastercard

    $32.8B FY2025 Net Revenue

    Mastercard reported $32.791 billion in FY2025 net revenue and $14.968 billion in net income.

31. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

32. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

33. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

34. 2026Mastercard

    BVNK Adds Stablecoin Infrastructure

    Mastercard closed its acquisition of stablecoin infrastructure firm BVNK on August 3, 2026, for up to $1.8 billion including contingent payments. The deal extends the company's network to on-chain payments alongside cards and bank transfers.

Acquisitions

Questions about AstraZeneca vs Mastercard